Title of the panel discussion:
Beyond Equity: Navigating Non-Dilutive Financing for Growth
Panel discussion summary
Equity is not the only path to fund innovation. This panel explores how biotech companies—from early stage to listed—can unlock capital through non-dilutive strategies. Our expert panelists from Switzerland and the United States will delve into early pharma collaborations / R&D partnerships, state-sponsored funding options and location packages, the power of royalty monetization, and value-creating outlicensing or spin-off structures. The session will highlight practical deal structures, key Swiss law and tax aspects, and real-world lessons on how to finance growth while preserving equity and strategic flexibility.
Date, time and room information
Tuesday, May 5, 12:15 - 13:00, room Shanghai 3+4
Moderation
| Name | Position | Institution |
|---|---|---|
| Daniel Häusermann | Partner | Homburger |
Panelists
| Name | Position | Institution |
|---|---|---|
| Fabian Meier | Partner | Ernst & Young |
| Hannah England | Partner | Ropes & Gray |
| Vincent Reardon | Partner | Vischer |
| Maurus Winzap | Partner | Walder Wyss |
Swiss Biotech Association
